Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASD

NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Asso

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples

Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi

Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company dev

Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst co

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provi

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (e

Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin deg

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OT

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.

Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (e

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog

Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status,

Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog

Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology

BBI-940 novel Kinesin degrader programThe acceptance of the BBI-940 IND enables Boundless to advance

BBI-940 IND accepted; initiation of first-in-human clinical trial on track  for the first half of 20

It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold

Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest.

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst

Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (e

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a B

Stocks That Hit 52-Week Highs On Friday

Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Tuesday

Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Tuesday

75 Biggest Movers From Yesterday

33 Stocks Moving In Monday's Mid-Day Session

Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018

88 Biggest Movers From Yesterday

70 Stocks Moving In Wednesday's Mid-Day Session